Efgartigimod (Vyvgart) in Myasthenia Gravis: Switching Off the System That Rescues Harmful Antibodies From Disposal
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Efgartigimod (Vyvgart) in Myasthenia Gravis: Switching Off the System That Rescues Harmful Antibodies From Disposal

A guide to efgartigimod (Vyvgart): the first FcRn blocker clears harmful antibodies without plasma exchange; in ADAPT, in myasthenia gravis with acetylcholine receptor antibodies, 68% responded versus 30% on placebo when added to usual treatment. The subcutaneous form, CIDP, how it is given and who should see a doctor first.

Efgartigimod (Vyvgart) in Myasthenia Gravis: Switching Off the System That Rescues Harmful Antibodies From Disposal
IgG antibodies last about three weeks because the body runs a dedicated service that rescues them from disposal and returns them to circulation — and in autoimmune disease it rescues the antibodies destroying your own tissue with the same diligence. Efgartigimod (Vyvgart) occupies that service entirely, and the harmful antibodies go to be recycled. In ADAPT, among patients with acetylcholine receptor antibodies, 68% responded versus 30% on placebo when added to usual treatment, and the subcutaneous form turned an infusion into an injection. We cover the mechanism, the cycle schedule and who should see a doctor first.

Key points

Efgartigimod (Vyvgart, approved by the FDA in December 2021) is the first drug to block the FcRn receptor: it switches off the mechanism that rescues antibodies from destruction, and pathogenic antibodies are disposed of.

WhereHow it helpsWhat human trials showed
Generalised myasthenia gravis in adults with acetylcholine receptor antibodiesadded to existing treatment, improves daily activitiesADAPT (Lancet Neurology, 2021), 167 patients, 77% with antibodies: an MG-ADL response in the first cycle — 68% versus 30% on placebo; odds ratio 4.95 (95% CI 2.21–11.53; p<0.0001) [1]
Tolerabilityno worse than on placeboin ADAPT adverse events — 77% versus 84% on placebo, serious ones 5% versus 8%; 4% in each group discontinued treatment; no deaths [1]
Subcutaneous forman injection instead of an infusionADAPT-SC (Neurotherapeutics, 2024): non-inferior to intravenous dosing for IgG reduction [2]
Chronic inflammatory demyelinating polyneuropathy (CIDP)indication extended in 2024 (ADHERE, Lancet Neurology, 2024) [3]—

How it helps

What Breaks in Myasthenia Gravis

A nerve commands a muscle chemically: it releases acetylcholine, and on the muscle the acetylcholine receptor — a kind of socket — receives it.

In myasthenia gravis the immune system makes antibodies against that socket. The nerve's command goes out, but there is nothing to receive it. Hence the characteristic picture: strength in the morning that fades by evening, a drooping eyelid, double vision, difficulty chewing and swallowing. In severe cases breathing is affected.

The key detail: the disease is sustained not by cells but by the antibodies themselves, circulating in the blood. So removing the antibodies helps — which is exactly the basis of plasma exchange, used in exacerbations for decades.

Why Antibodies Are So Long-Lived

An ordinary blood protein lasts hours. IgG antibodies last about three weeks. The reason is not molecular sturdiness but a separate rescue system.

Cells constantly take up whatever is in the blood, and captured proteins go for destruction. But IgG inside the cell binds the FcRn receptor, which carries it back out into the blood, past disposal.

Evolutionarily this is sensible: immune memory should last. But the system does not distinguish between an antibody protecting you from infection and one destroying your own muscle receptor. It rescues them all.

The Idea Behind the Drug

Efgartigimod is an antibody fragment altered to bind FcRn more tightly than ordinary IgG.

It occupies every rescue slot. The body's own antibodies can no longer return to the blood and are degraded by the usual route. IgG levels fall — and with them the quantity of pathogenic antibodies.

Plasma exchangeEfgartigimod
What it doesMechanically removes antibodies from plasmaSwitches off the mechanism that rescues them
Where it happensIn hospital, on a machineAn infusion, or an injection in subcutaneous form
Vascular accessRequiredNot required
SelectivityRemoves everythingLowers all IgG
RhythmBy exacerbationIn cycles, as symptoms return

How it is given

ParameterDetail
RouteIntravenous infusion or subcutaneous injection
ScheduleA cycle of 4 weekly administrations, then a break
When the next cycle startsOn returning symptoms, not by the calendar
MonitoringSymptoms, IgG level, signs of infection
VaccinationPlanned in advance, before treatment starts

The cyclical schedule is not a compromise but a consequence of the mechanism: the drug lowers antibody levels temporarily, the body gradually restores them, and treatment is repeated as symptoms return.

Who should see a doctor first

Infections and vaccination. The drug lowers all IgG, not only the harmful kind, so anti-infective defence is temporarily weakened. According to the US prescribing information, efgartigimod may increase the risk of infections: in ADAPT, urinary tract infections occurred in 10% versus 5% on placebo and respiratory tract infections in 33% versus 29%, mostly mild or moderate [4]. With an active infection, dosing is postponed; with a serious one, the infection is treated and a decision is made whether to pause the drug until recovery. Needed vaccinations are assessed before a cycle starts; live vaccines are not recommended during treatment [4].

Who It Is Not For

▸ Anyone who has had a severe allergic reaction to efgartigimod or any component of the product (anaphylaxis and a drop in blood pressure with fainting have been described).
▸ Anyone with an active infection — treatment waits until it resolves.
▸ As emergency care in a myasthenic crisis: this is scheduled therapy, not a resuscitation measure.
▸ Anyone without a confirmed diagnosis and a defined antibody status: therapy is not chosen without them.
▸ As a patient-initiated replacement for baseline therapy.

Bottom Line

▸ A new point of attack: not suppressing immunity but switching off the system that prolongs antibody life.
▸ Efficacy demonstrated in patients with acetylcholine receptor antibodies: 68% response versus 30% on placebo.
▸ Tolerability in the trial was no worse than placebo, which is not obvious for such a mechanism.
▸ The subcutaneous form replaced the infusion with an injection without losing the effect on IgG.

Treatment can be discussed at a consultation; the drug can be ordered here.

References

1. Howard JF Jr, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20(7):526–536. PMID 34146511

2. Howard JF Jr, et al. Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC). Neurotherapeutics. 2024;21(5):e00378. PMID 39227284

3. Allen JA, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy (ADHERE). Lancet Neurol. 2024;23(10):1013–1024. PMID 39304241

4. VYVGART (efgartigimod alfa) — US Prescribing Information, argenx.

Source: Efgartigimod (Vyvgart) in Myasthenia Gravis: Switching Off the System That Rescues Harmful Antibodies From Disposal — universum.earth. Dr. Pereligyn.

Come back
Request a call back